Evaluating blood flow changes in patients with atherosclerotic vascular disease undergoing rehabilitation
Evolution of Hemodynamic Parameters in People with Atherosclerotic Vascular Disease Referred to a Secondary Prevention and Cardiovascular Rehabilitation (PREV) Program: a Prospective Cohort Study.
This study tests how a 12-week rehabilitation program affects blood flow in the feet of people with atherosclerotic vascular disease and tracks their health over the following year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Laval University Academic / other |
| Locations | 1 site (Lévis, Quebec) |
| Trial ID | NCT06701032 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the hemodynamic changes in the forefoot of patients with atherosclerotic vascular diseases, such as coronary artery disease and peripheral artery disease, who are participating in a 12-week cardiovascular rehabilitation program. It will also document the characteristics of these patients and track their outcomes, including any complications, for up to one year after completing the program. The focus is on understanding how rehabilitation impacts blood flow and overall cardiovascular health.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and older diagnosed with various forms of atherosclerotic vascular disease who are admitted to the PREV program.
Not a fit: Patients unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve rehabilitation strategies for patients with atherosclerotic vascular disease, leading to better health outcomes.
How similar studies have performed: Other studies have shown positive outcomes with cardiovascular rehabilitation programs, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any individual aged 18 years and older who has been diagnosed with peripheral artery disease, coronary artery disease, angina, ischemic heart failure, transient ischemic attack or ischemic stroke (non-cardioembolic, non-hemorrhagic); * Have been admitted to the PREV program; Exclusion Criteria: * Being not able to give written informed consent;
Where this trial is running
Lévis, Quebec
- CLSC de Lévis - Programme PREV du CISSS de Chaudière-Appalaches — Lévis, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: Jérôme Patry, DPM, MD, MSc
- Email: jerome.patry.1@ulaval.ca
- Phone: 418-835-7121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.